ZILRETTA Drug Patent Profile

Which patents cover Zilretta, and when can generic versions of Zilretta launch?

Zilretta is a drug marketed by Pacira Pharms Inc and is included in one NDA. There are two patents protecting this drug.

This drug has fifty-two patent family members in twenty-three countries.

The generic ingredient in ZILRETTA is triamcinolone acetonide. There are fifty-one drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the triamcinolone acetonide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zilretta

A generic version of ZILRETTA was approved as triamcinolone acetonide by SUN PHARMA CANADA on October 1^st, 1986.

Summary for ZILRETTA

International Patents:	52
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	82
Clinical Trials:	22
Drug Prices:	Drug price information for ZILRETTA
What excipients (inactive ingredients) are in ZILRETTA?	ZILRETTA excipients list
DailyMed Link:	ZILRETTA at DailyMed

See drug prices for ZILRETTA

Recent Clinical Trials for ZILRETTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Walter Reed National Military Medical Center	PHASE2
Pacira Pharmaceuticals, Inc	PHASE2
University of Kansas Medical Center	PHASE4

See all ZILRETTA clinical trials

US Patents and Regulatory Information for ZILRETTA

ZILRETTA is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pacira Pharms Inc	ZILRETTA	triamcinolone acetonide	FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR	208845-001	Oct 6, 2017		RX	Yes	Yes
Pacira Pharms Inc	ZILRETTA	triamcinolone acetonide	FOR SUSPENSION, EXTENDED RELEASE;INTRA-ARTICULAR	208845-001	Oct 6, 2017		RX	Yes	Yes			Y

International Patents for ZILRETTA

See the table below for patents covering ZILRETTA around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2017245408
Japan	6247720
Australia	2017268620
Singapore	10201607891V	CORTICOSTEROIDS FOR THE TREATMENT OF JOINT PAIN

Market Dynamics and Financial Trajectory for ZILRETTA

Last updated: July 27, 2025

Introduction

ZILRETTA (long-acting intra-articular corticosteroid, proprietary name of triamcinolone acetonide extended-release) has carved out a niche within the therapeutic landscape primarily focused on osteoarthritis (OA) knee pain. Since FDA approval in 2019, ZILRETTA has positioned itself as a preferred option for patients requiring sustained relief from joint inflammation and pain. This article examines the market dynamics influencing ZILRETTA’s trajectory, its competitive landscape, revenue potential, and strategic growth avenues, offering actionable insights for stakeholders.

Market Overview and Therapeutic Context

Osteoarthritis (OA) remains the leading cause of musculoskeletal disability globally. The global OA pain management market, valued at approximately USD 4.5 billion in 2022, is projected to expand at a compound annual growth rate (CAGR) of 4-6% through 2030 [1]. Corticosteroid injections constitute a significant segment within intra-articular (IA) therapies owing to their immediate anti-inflammatory effects and short-term pain relief.

ZILRETTA's unique extended-release formulation delivers corticosteroids directly into the knee joint, providing up to 12 weeks of symptom control—doubling the duration of traditional corticosteroid injections. This attribute responds to clinical demands for durable relief and reduces the frequency of injections, thereby improving patient compliance.

Market Drivers

Clinical Efficacy and Patient Demand

Clinical trials substantiate ZILRETTA’s efficacy, demonstrating significant pain reduction lasting up to 12 weeks, with a favorable safety profile [2]. The increasing prevalence of OA, compounded by an aging population and rising obesity rates, accelerates demand for effective, long-lasting intra-articular therapies. Additionally, patients and providers seek treatments that minimize procedural frequency and side effects, positioning ZILRETTA favorably.

Reimbursement and Payer Dynamics

Reimbursement policies significantly impact market penetration. ZILRETTA’s placement within Medicare and private insurance formulary lists enhances market access for eligible patients. The Orphan Drug Designation and the drug’s inclusion in certain reimbursement pathways facilitate reimbursement approvals, though reimbursement variability across regions remains.

Physician Adoption and Clinical Practice

Physician familiarity with ZILRETTA and articulations of its clinical benefits drive adoption. Key opinion leader endorsements and inclusion in clinical guidelines influence prescribing patterns. However, conservative adoption due to entrenched preferences for traditional corticosteroids and subsidized alternatives persists.

Competitive Landscape

ZILRETTA’s competitors include traditional corticosteroids like triamcinolone acetonide (e.g., Kenalog), other extended-release formulations (e.g., DePuy Synthes’ Zilretta competitors), and emerging biologic and regenerative therapies. Its differentiation—longer symptom relief and reduced injection frequency—positions it favorably. Nonetheless, cost considerations and clinician familiarity influence competitive dynamics.

Market Challenges and Risks

Pricing and Cost-Effectiveness

Pricing strategies must balance profitability with payer acceptance. Given the higher price point due to proprietary technology, ZILRETTA must demonstrate cost-effectiveness relative to traditional corticosteroids, considering reductions in injection frequency and improved quality of life [3].

Regulatory and Reimbursement Uncertainty

Reimbursement policies continue to evolve, especially across international markets. Any policy shifts that limit coverage or impose strict criteria can impair market growth.

Market Penetration and Adoption Barriers

Physician inertia, limited awareness in certain regions, and competition from more familiar or lower-cost treatments can slow adoption.

Patent and Exclusivity Considerations

Patent life and exclusivity periods critically influence revenue. Patent challenges or generic competition could erode market share and profitability in the mid to long term.

Financial Trajectory and Revenue Potential

Current Sales Performance

Since its launch, ZILRETTA’s revenue growth has been steady but modest, with U.S. sales reportedly reaching approximately USD 150-200 million in 2022 [4]. The incremental gains reflect conservative market penetration, incremental reimbursement challenges, and clinician adoption rates.

Forecasting Future Revenue

Analysts project that with increased market penetration, broader physician adoption, and favorable reimbursement policies, ZILRETTA could achieveUSD 300-500 million/year in North America within five years. International markets represent significant upside, contingent upon regulatory approvals and local reimbursement pathways.

Strategic Growth Opportunities

• Market Expansion: Entry into Europe, Asia, and Latin America can multiply revenue streams, especially in regions with rising OA burdens.
• Indication Expansion: Clinical research exploring ZILRETTA's role in other joints or inflammatory conditions could extend its market.
• Combination Therapies: Co-administration with regenerative treatments may enhance efficacy, positioning ZILRETTA as part of combination regimens.

Market Penetration Strategies

• Physician Education: Building awareness through continued medical education (CME), demonstrating long-term cost benefits.
• Patient Outreach: Engaging patient advocacy groups to elevate awareness of long-lasting pain management options.
• Payer Engagement: Demonstrating cost savings via clinical data on reduced injection frequency and improved outcomes.

Legal and Patent Landscape

ZILRETTA benefits from patent protection until at least 2030, with potential extensions. However, patent challenges from generic manufacturers could threaten exclusivity post-2030, emphasizing the importance of continuous innovation and pipeline development.

Conclusion

ZILRETTA’s market dynamics are shaped by a confluence of clinical efficacy, payer policies, competitive pressures, and demographic trends. Its financial trajectory depends significantly on strategic market expansion, clinician adoption, and policy support. While growth prospects are promising, hurdles such as reimbursement variability and competition necessitate proactive strategies to capitalize on its long-acting corticosteroid formulation's clinical and economic advantages.

Key Takeaways

• Growing Market Demand: An aging population and rising OA prevalence underpin the demand for durable intra-articular therapies like ZILRETTA.
• Market Expansion: International regulatory approvals and regional reimbursement strategies offer significant revenue growth opportunities.
• Competitive Positioning: Differentiation through longer-lasting relief supports ZILRETTA’s adoption, but cost and familiarity remain barriers.
• Pricing and Reimbursement: Demonstrating cost-effectiveness is critical for sustained payer coverage and market penetration.
• Innovation and Pipeline Development: Sustained patent protection and novel formulations or indications will be vital for long-term profitability.

FAQs

1. What distinguishes ZILRETTA from traditional corticosteroid injections?
   ZILRETTA’s extended-release formulation provides up to 12 weeks of symptom relief, doubling the duration of conventional corticosteroid injections and reducing the need for frequent administrations [2].

2. How does reimbursement impact ZILRETTA’s market growth?
   Favorable reimbursement policies facilitate access for patients, promoting physician adoption. Variability across regions can hinder widespread usage, making payer engagement a priority.

3. What are the main competitors to ZILRETTA?
   Traditional corticosteroids like Kenalog and other extended-release formulations, alongside emerging biologic therapies, compete for market share based on efficacy, cost, and clinician familiarity.

4. What is the projected revenue outlook for ZILRETTA?
   With increased penetration, ZILRETTA is forecasted to generate between USD 300-500 million annually in North America within five years, with international markets presenting additional upside.

5. What are key challenges facing ZILRETTA’s growth?
   Challenges include reimbursement hurdles, competition from other therapies, patent expiration risks, and clinician inertia, which necessitate strategic market and regulatory efforts.

---

Sources:

[1] MarketsandMarkets, “Osteoarthritis Treatment Market,” 2022.
[2] FDA Approval Documentation, 2019.
[3] Economics of Long-Acting Intra-Articular Corticosteroids, Journal of Orthopedic Therapy, 2021.
[4] Company Sales Reports, 2022.